Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 2:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lacosamide Clear all
Recruiting Phase 4 Interventional

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

NCT06866691
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
levetiracetam, lacosamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Withdrawn Phase 3 Interventional

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

NCT02726867
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

NCT01484977
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
30
States / cities
Huntsville, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures

NCT02408549
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lacosamide Oral Solution
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
16
States / cities
Little Rock, Arkansas • Santa Monica, California • Colorado Springs, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

NCT00401830
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Lacosamide, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
25
States / cities
Litchfield Park, Arizona • Santa Ana, California • Walnut Creek, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

NCT04519645
View directory record Official record
Conditions
Electroencephalographic Neonatal Seizures, Epilepsy
Interventions
Lacosamide intravenous, Lacosamide oral, Active Comparator
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
Up to 28 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

IV Lacosamide: The Safety of Intravenous Lacosamide

NCT01981447
View directory record Official record
Conditions
Epilepsy
Interventions
IV Lacosamide
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
4 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

NCT03897348
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Lacosamide 100 mg, Lacosamide 200 mg
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy

NCT00938912
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older

NCT01465997
View directory record Official record
Conditions
Epilepsy, Monotherapy
Interventions
Lacosamide, Carbamazepine-Controlled Release (CBZ-CR)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
Not listed
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Alabaster, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Active, not recruiting Phase 1 Interventional

STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis

NCT05603702
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery
Interventions
Lacosamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Stanford, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Antiepileptics in Patients on CRRT

NCT03632915
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Renal Failure, Pharmacokinetics
Interventions
Levetiracetam, Lacosamide, Phenytoin, Phenobarbital, Ketamine, Valproic Acid
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional

Cognitive and Behavioral Effects of Lacosamide

NCT01175954
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
Evan Fertig
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 16, 2026, 2:18 AM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Not listed No phase listed Observational

A Pharmacogenomic Exploration of Lacosamide Response

NCT01399528
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Royal College of Surgeons, Ireland
Other
Eligibility
18 Years to 65 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Sep 16, 2026, 2:18 AM EDT
Terminated Not applicable Interventional Results available

A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

NCT01110187
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
lacosamide, Fosphenytoin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01190098
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Lacosamide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

NCT00235443
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
32 Years to 81 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
84
States / cities
Anniston, Alabama • Hoover, Alabama • Huntsville, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

NCT00530855
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
77
States / cities
Alabaster, Alabama • Birmingham, Alabama • Northport, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 16, 2026, 2:18 AM EDT
Completed No phase listed Observational

Effects of Adjunctive Lacosamide on Mood States and Quality of Life (QOL) in Patients With Epilepsy

NCT01296880
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
17 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

NCT01118962
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 16, 2026, 2:18 AM EDT
Completed Phase 4 Interventional

The Safety of Intravenous Lacosamide

NCT00832884
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
4 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 16, 2026, 2:18 AM EDT